FOXO4-DRI · 10 mg
Published- batch · LOT
- B-2026-FOXO4DRI-10-001
- Laboratory
- Uzorak
- purity
- 99.97%
- Test date
- 27.07.2026
Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
A senolytic peptide: in mice it selectively cleared the "ageing" cells that harm tissues. A research tool of ageing biology from the landmark 2017 Cell paper.
Selected size: 10 mg
10 mg analysis published
Research, properties and limitations
AI can make mistakes
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (3 consecutive days) | 0.5–1 mg subcutaneously per day | Starting dose |
| Main cycle (3 consecutive days) | 2–2.5 mg subcutaneously per day | Increase if needed |
| Cycle ceiling; cycle repeated 2–3x per year | up to 5 mg subcutaneously per day | Maximum in this schedule |
Research overview · reference
Below is a short summary of what the authors of published studies reported. It is not medical advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Tolerability in the models (platelet counts monitored) | Cell cultures and mice; platelet counts assessed before treatment and 30 days afterward | The authors’ tolerability description concerns those experimental conditions; the experiments provide no human adverse-reaction frequencies | [1] |
FAQ
Find answers to questions about FOXO4-DRI and related materials.
FOXO4-DRI is an engineered senolytic peptide: it intervenes in the conversation between two proteins inside an ageing (senescent) cell — FOXO4 and p53. Normally that interaction keeps p53 "locked up" and stops the cell from triggering its own destruction; the peptide breaks the bond — and the senescent cell goes into apoptosis, while healthy cells, which have no such bond, remain untouched.
Source / documentationFrom a 2017 paper in Cell (the Erasmus MC group, Rotterdam): in aged mice, clearing senescent cells with this peptide was associated with restored physical fitness, fur density and kidney function. Since then FOXO4-DRI has been used in models of vascular ageing, cartilage, keloid scarring and age-related testosterone deficiency. Details are in the FOXO4-DRI monograph in our wiki.
Source / documentationSenolytics are a class of compounds that selectively remove senescent cells: cells that have stopped dividing but have not died and secrete inflammatory signals into the surrounding tissue. The idea of the approach is an occasional "clean-up" of such cells instead of daily exposure. FOXO4-DRI is one of the first peptide senolytics.
Source / documentationThe dry powder is dissolved and injected under the skin in short courses of several consecutive days, with breaks between cycles — the senolytic logic is an occasional "clean-up", not daily intake. Reference points are in the dosing guide on this page.
Source / documentationNo — honestly: there are no clinical studies in humans; the whole base is preclinical (cells and animals). So there is neither a proven dose nor a human safety profile. A full review of the known data is in the FOXO4-DRI monograph in our wiki.
Source / documentationKeep the dry powder in a dry, dark place at a low temperature; once dissolved, store it in the refrigerator and do not freeze it again. Details are in the FOXO4-DRI guide on this page.
Source / documentationYou can buy FOXO4-DRI right on this page of our store: current prices and stock are shown in the product card. We deliver across Ukraine with Nova Poshta — to a branch, a parcel locker, or by courier. Payment is by card, by crypto (with a 5% discount), or on delivery. Every vial ships with the certificate of analysis (COA) for its exact batch.
Source / documentationCertificates shown: 1
Share your experience
No reviews yet. Tell others what you think of this product.
FOXO4-DRI is an engineered senolytic peptide: it intervenes in the conversation between two proteins inside an ageing (senescent) cell — FOXO4 and p53. Normally that interaction keeps p53 "locked up" and stops the cell from triggering its own destruction; the peptide breaks the bond — and the senescent cell goes into apoptosis, while healthy cells, which have no such bond, remain untouched.
Where the fame comes from: a 2017 paper in Cell (the Erasmus MC group, Rotterdam) showed in aged mice that clearing senescent cells with this peptide was associated with restored physical fitness, fur density and kidney function. Since then FOXO4-DRI has been used in models of vascular ageing, cartilage, keloid scarring and age-related testosterone deficiency. Details are in the FOXO4-DRI monograph.
Honestly about the limits: there are no clinical studies in humans — the whole base is preclinical. How it is used: the dry powder is dissolved and injected under the skin in short courses of several consecutive days, with breaks between cycles — the senolytic logic is an occasional "clean-up", not daily intake. Reference points are in the dosing guide; the full line is in the longevity category.
Every batch is purity-tested by HPLC, and the certificate of analysis (COA) for your exact batch is in our COA archive. Keep the dry powder in a dry, dark place at a low temperature, and the dissolved solution in the refrigerator.